Page 6 - Precigen News Today

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

/PRNewswire/ -- Precigen, Inc. (NASDAQ: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

– Enrollment complete in Phase 1 study of PRGN-3006 UltraCAR-T® in acute myeloid leukemia (AML); enrollment ongoing in Phase 1b dose expansion study; Mayo...

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

Precigen, Inc. (NASDAQ:PGEN – Get Rating) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $2.30 and traded as low as $1.23. Precigen shares last traded at $1.35, with a volume of 2,668,070 shares changing hands. Separately, HC Wainwright reissued a […]

Equities research analysts expect Precigen, Inc. (NYSE:PGEN – Get Rating) to report sales of $46.74 million for the current quarter, Zacks reports. Three analysts have made estimates for Precigen’s earnings, with estimates ranging from $22.60 million to $85.00 million. Precigen reported sales of $33.58 million during the same quarter last year, which would suggest a […]

Analysts expect Precigen, Inc. (NYSE:PGEN – Get Rating) to announce earnings per share (EPS) of ($0.01) for the current quarter, Zacks reports. Three analysts have issued estimates for Precigen’s earnings, with the lowest EPS estimate coming in at ($0.14) and the highest estimate coming in at $0.19. Precigen reported earnings of ($0.10) per share during […]

Precigen (NASDAQ:PGEN – Get Rating)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued to investors on Monday, TipRanks reports. They presently have a $10.00 target price on the biotechnology company’s stock. Separately, Zacks Investment Research upgraded Precigen from a “hold” rating to a “buy” rating and set a $1.50 […]

– Fast Track designation received for PRGN-3006 UltraCAR-T®, an important milestone for patients with relapsed or refractory acute myeloid leukemia, a rapidly...